NLRP3-IN-44, with the CAS number 3040298-34-5, is a small molecule inhibitor specifically targeting the NLRP3 inflammasome, a critical component of the innate immune system involved in the inflammatory response. This compound is characterized by its ability to modulate the activation of NLRP3, thereby influencing the production of pro-inflammatory cytokines such as IL-1β and IL-18. NLRP3-IN-44 is of particular interest in research related to various inflammatory diseases, including autoimmune disorders and metabolic syndromes, where excessive inflammasome activation is implicated. The compound's structure typically includes functional groups that enhance its binding affinity to the NLRP3 protein, contributing to its inhibitory effects. In preclinical studies, NLRP3-IN-44 has shown promise in reducing inflammation and providing therapeutic benefits, although further research is necessary to fully understand its pharmacokinetics, safety profile, and potential clinical applications. As with any investigational compound, its use is primarily confined to research settings until more comprehensive data is available.

NLRP3-IN-44

3040298-34-5: NLRP3-IN-44, with the CAS number 3040298-34-5, is a small molecule inhibitor specifically targeting the NLRP3 inflammasome, a critical component of the innate immune system involved in the inflammatory response. This compound is characterized by its ability to modulate the activation of NLRP3, thereby influencing the production of pro-inflammatory cytokines such as IL-1β and IL-18. NLRP3-IN-44 is of particular interest in research related to various inflammatory diseases, including autoimmune disorders and metabolic syndromes, where excessive inflammasome activation is implicated. The compound's structure typically includes functional groups that enhance its binding affinity to the NLRP3 protein, contributing to its inhibitory effects. In preclinical studies, NLRP3-IN-44 has shown promise in reducing inflammation and providing therapeutic benefits, although further research is necessary to fully understand its pharmacokinetics, safety profile, and potential clinical applications. As with any investigational compound, its use is primarily confined to research settings until more comprehensive data is available.

<p>NLRP3-IN-44 (compound P33), an orally active (approximately 62%) and potent inhibitor of NLRP3, exhibits a dissociation constant (K D) of 17.5 nM. This compound is crucial in the research of diseases mediated by the NLRP3 inflammasome.</p>

CAS 3040298-34-5

NLRP3-IN-44

NLRP3-IN-44

Ref: TM-T89953